{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-028366","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2025-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.926177+00:00","generated_at":"2026-05-23T22:45:20.694870+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"MoonLake secures up to $500M non-dilutive loan from Hercules Capital; $75M drawn at close","bullets":["Up to $500M non-dilutive term loan facility from Hercules Capital; $75M funded at close on March 31, 2025.","Additional tranches up to $125M upon VELA Phase 3 HS success; further tranches for PsA and BLA acceptance.","Facility matures April 1, 2030; interest rate prime+1.45% (floor 8.45%), 0.25% reduction on FDA BLA acceptance.","Company had $448M cash (from 10-K); combined facility expected to fund sonelokimab launch in 2027.","Capital Markets Update April 29, 2025: VELA baseline characteristics, primary endpoint readout timing, and Phase 2 LEDA interim data."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-028366","json":"https://secwatch.observer/filing/0001213900-25-028366.json","markdown":"https://secwatch.observer/filing/0001213900-25-028366.md","text":"https://secwatch.observer/filing/0001213900-25-028366.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000121390025028366/0001213900-25-028366-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000121390025028366/ea0236970-8k_moonlake.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T22:45:20.694870+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}